Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 5000 shares changing hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Price Performance
The stock has a market cap of C$1.33 million, a price-to-earnings ratio of -1.00 and a beta of -0.02. The stock has a fifty day simple moving average of C$0.01 and a 200-day simple moving average of C$0.02. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last released its earnings results on Thursday, August 29th. The company reported C($0.01) earnings per share (EPS) for the quarter. The business had revenue of C$0.16 million during the quarter. As a group, equities research analysts expect that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current year.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- How to Use the MarketBeat Excel Dividend Calculator
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Which Wall Street Analysts are the Most Accurate?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Investing in the High PE Growth Stocks
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
